Latest Information
April 26, 2012
Two recent studies have reported on the possible utility of assessing pre-treatment neutrophil-to-lymphocyte ratio (NLR) as a prognostic factor in mRCC.
April 26, 2012
A small phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases (FLT3), has concluded that the novel agent has no clinical activity and excessive toxicity, and should not be developed further for mRCC.
March 31, 2012
Patients with papillary renal cell carcinoma, the second most common kidney cancer subtype, face a low risk of tumour recurrence and cancer-related death after surgery.
Print this page Tell A Friend Add to Favorites

Ultrasound Not Inferior for Sizing Renal Masses

January 06, 2012
Jody A. Charnow

Ultrasound imaging works as well as computed tomography (CT) and magnetic resonance imaging (MRI) for evaluating renal mass size, a new study suggests.

The finding “might be beneficial for long-term active surveillance protocols to contain healthcare costs and reduce radiation exposure,” researchers concluded.

Phillip Mucksavage, MD, of the University of California in Irvine, and colleagues studied 116 patients who underwent ultrasound imaging prior to definitive therapy for a renal mass. These patients also underwent CT (66 patients) or MRI (80 patients). Thirty-three patients underwent all three imaging modalities. The average pathologic tumor size for the entire cohort was 4.45 cm.

The renal mass size differences between CT and MRI compared with ultrasound were nonsignificant (less than 3.5%), Dr. Mucksavage's team reported in Urology (2012;79:28-31). For patients who underwent ultrasound and CT, the average tumor size was 4.73 cm and 4.57 cm, respectively. For those who underwent ultrasound and MRI, the average tumor size was 4.65 cm and 4.49 cm, respectively. For patients who underwent ultrasound, CT, and MRI, the average tumor size was 4.47 cm, 4.27 cm, and 4.29 cm, respectively.

In an accompanying editorial, Maxwell V. Meng, MD, of the University of California, San Francisco, School of Medicine, observed: “Although the urologist is traditionally most comfortable interpreting cross-sectional images, particular CT, we must question the established paradigms and evolve to incorporate comparable modalities with less morbidity for the patient and reduced cost for the healthcare system.”

From the February 2012 Issue of Renal And Urology News
Filed Under: Uncategorized